Cargando…
Comparison of the incidence of contrast-induced nephropathy after primary PCI in patients receiving high-dose rosuvastatin and atorvastatin
INTRODUCTION: Contrast-induced nephropathy (CIN) is associated with increased disability and death. Randomized clinical trial studies have shown that short-term treatment with statins prior to cardiac intervention was capable of reducing the incidence of CIN. Therefore, the aim of this study was to...
Autores principales: | Golshani, Samad, Tavasoli, Parastoo, Farsavian, Ali Asghar, Farsavian, Hossein, Charati, Jamshid Yazdani |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9254854/ https://www.ncbi.nlm.nih.gov/pubmed/35800554 http://dx.doi.org/10.4103/jfmpc.jfmpc_1344_21 |
Ejemplares similares
-
Efficacy of intravenous eptifibatide in primary percutaneous coronary intervention patients
por: Jalalian, Rozita, et al.
Publicado: (2021) -
Transient lateral rectus palsy associated with acute coronary syndrome treated with percutaneous coronary intervention: a case report
por: Farsavian, Ali Asghar, et al.
Publicado: (2023) -
Remote ischemic preconditioning to reduce contrast-induced acute kidney injury in chronic kidney disease: a randomized controlled trial
por: Ghaemian, Ali, et al.
Publicado: (2018) -
Comparison between rosuvastatin and atorvastatin for the prevention of contrast-induced nephropathy in patients with STEMI undergoing primary percutaneous coronary intervention
por: Firouzi, Ata, et al.
Publicado: (2018) -
Comparison of the Efficacy of Rosuvastatin versus Atorvastatin in Preventing Contrast Induced Nephropathy in Patient with Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention
por: Liu, Yong, et al.
Publicado: (2014)